Skip to content. | Skip to navigation


Personal tools
You are here: Research @ McMaster > Research Chairs > Jonathan Schertzer

Research at McMaster University faded

Jonathan Schertzer

Jonathan Schertzer

Canada Research Chair in Metabolic Inflammation

Tier 2: 2017-07-01


Department of Biochemistry & Biomedical Sciences Profile

Research involves

Using experimental and preclinical methods to understand the links between immune and metabolic systems.

Research relevance

This research will improve existing treatments, and lead to the development of new treatments, for obesity-related metabolic diseases like prediabetes and type 2 diabetes.

Getting the Skinny of Prediabetes

Metabolic diseases can lead to complications like heart attacks, stroke, and even infection, claiming millions of lives worldwide each year. Obesity, which increases blood insulin and glucose, is a significant factor in the development of metabolic diseases like prediabetes and type 2 diabetes. Over half of Canada's population is overweight or obese and potentially at risk. 

Researchers aren't sure why, but not all obese individuals will develop a metabolic disease. Thankfully, Jonathan Schertzer, Canada Research Chair in Metabolic Inflammation, is trying to get the skinny on it.  

Most people who develop prediabetes will later develop type 2 diabetes, but this process could take decades. Prediabetes is reversible so it is crucial to use that window of time to prevent the onset of type 2 diabetes.  

Schertzer and his research team are using experimental and preclinical approaches to understand the link between the immune and metabolic systems.  They will also examine how existing drugs impact blood glucose.  

By understanding how our bodies interact with bacteria and therapeutic drugs during obesity, and how inflammation is triggered, Schertzer's research team aims to improve the safety and success of existing therapies and promote the development of new and innovative treatments for obesity-related diseases.